Related Experiment Videos
The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke?
Tobias Boeckh-Behrens1, Justus Kleine2, Johannes Kaesmacher1
1Department of Neuroradiology, University Hospital Rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675 Munich, Germany.
Thrombosis Journal
|April 18, 2017
Summary
Higher CD31+ cell density in stroke thrombi correlates with better early recovery in acute ischemic stroke patients. This suggests CD31 may offer neuroprotection and improve clinical outcomes.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Research
Background:
- CD31 (platelet-endothelial cell adhesion molecule-1) is a transmembrane receptor with known immunomodulatory functions.
- Its role in acute ischemic stroke is being investigated for potential neuroprotective effects by modulating secondary immune responses.
Purpose of the Study:
- To investigate the density of CD31+ cells within mechanically extracted thrombi from stroke patients.
- To determine if CD31+ cell presence is associated with improved clinical outcomes in acute ischemic stroke.
Main Methods:
- Analysis of 86 thrombus specimens from patients undergoing mechanical recanalization for large anterior circulation stroke.
- Quantification of CD31+ cell density and comparison with early clinical outcome data (ΔNIHSS).
Main Results:
- A positive correlation was observed between CD31+ cell density and early patient improvement (r=0.283, p=0.012).
- This association strengthened after excluding early hospital deaths (r=0.371, p=0.001) and remained significant in multivariate analysis (p=0.049).
Conclusions:
- A consistent relationship exists between CD31+ cells and early clinical improvement in acute ischemic stroke.
- CD31's immunomodulatory and potential neuroprotective properties suggest it could be a therapeutic target for stroke patients.